These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 28607587)
1. Impact of CD44 expression on radiation response for bladder cancer. Wu CT; Lin WY; Chang YH; Chen WC; Chen MF J Cancer; 2017; 8(7):1137-1144. PubMed ID: 28607587 [No Abstract] [Full Text] [Related]
2. Predictive Value of CD44 in Muscle-Invasive Bladder Cancer and Its Relationship with IL-6 Signaling. Wu CT; Lin WY; Chen WC; Chen MF Ann Surg Oncol; 2018 Nov; 25(12):3518-3526. PubMed ID: 30128900 [TBL] [Abstract][Full Text] [Related]
3. Expression and prognostic significance of cancer stem cell markers CD24 and CD44 in urothelial bladder cancer xenografts and patients undergoing radical cystectomy. Hofner T; Macher-Goeppinger S; Klein C; Schillert A; Eisen C; Wagner S; Rigo-Watermeier T; Baccelli I; Vogel V; Trumpp A; Sprick MR Urol Oncol; 2014 Jul; 32(5):678-86. PubMed ID: 24631171 [TBL] [Abstract][Full Text] [Related]
4. Development of a therapy against metastatic bladder cancer using an interleukin-2 surface-modified MB49 bladder cancer stem cells vaccine. Zhu YT; Pang SY; Lei CY; Luo Y; Chu QJ; Tan WL Stem Cell Res Ther; 2015 Nov; 6():224. PubMed ID: 26566931 [TBL] [Abstract][Full Text] [Related]
5. Impact of Expression of CD44, a Cancer Stem Cell Marker, on the Treatment Outcomes of Intensity Modulated Radiation Therapy in Patients With Oropharyngeal Squamous Cell Carcinoma. Motegi A; Fujii S; Zenda S; Arahira S; Tahara M; Hayashi R; Akimoto T Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):461-8. PubMed ID: 26867875 [TBL] [Abstract][Full Text] [Related]
6. Initial results of retrospective study: preoperative transurethral excision plus chemotherapy and radiation therapy and trial of bladder preservation. Gamal El-Deen HS J Egypt Natl Canc Inst; 2007 Jun; 19(2):133-46. PubMed ID: 19034344 [TBL] [Abstract][Full Text] [Related]
7. Expression of CD44 splice variants in bladder cancer. Kan M; Furukawa A; Aki M; Kanayama H; Kagawa S Int J Urol; 1995 Nov; 2(5):295-301. PubMed ID: 8749947 [TBL] [Abstract][Full Text] [Related]
8. The value of pathologic factors in predicting cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate. Frazier HA; Robertson JE; Dodge RK; Paulson DF Cancer; 1993 Jun; 71(12):3993-4001. PubMed ID: 8508365 [TBL] [Abstract][Full Text] [Related]
9. Radiobiological characteristics of cancer stem cells from esophageal cancer cell lines. Wang JL; Yu JP; Sun ZQ; Sun SP World J Gastroenterol; 2014 Dec; 20(48):18296-305. PubMed ID: 25561796 [TBL] [Abstract][Full Text] [Related]
10. The CD44 standard isoform contributes to radioresistance of pancreatic cancer cells. Tsubouchi K; Minami K; Hayashi N; Yokoyama Y; Mori S; Yamamoto H; Koizumi M J Radiat Res; 2017 Nov; 58(6):816-826. PubMed ID: 29106581 [TBL] [Abstract][Full Text] [Related]
11. Expression and function role of DNA methyltransferase 1 in human bladder cancer. Wu CT; Wu CF; Lu CH; Lin CC; Chen WC; Lin PY; Chen MF Cancer; 2011 Nov; 117(22):5221-33. PubMed ID: 21523767 [TBL] [Abstract][Full Text] [Related]
12. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Tanei T; Morimoto K; Shimazu K; Kim SJ; Tanji Y; Taguchi T; Tamaki Y; Noguchi S Clin Cancer Res; 2009 Jun; 15(12):4234-41. PubMed ID: 19509181 [TBL] [Abstract][Full Text] [Related]
13. A multi-institutional study of bladder-preserving therapy for stage II-IV bladder cancer: A Korean Radiation Oncology Group Study (KROG 14-16). Byun SJ; Park W; Cho KH; Cho J; Chang AR; Kang KM; Kim JH; Kim JH PLoS One; 2019; 14(1):e0209998. PubMed ID: 30653591 [TBL] [Abstract][Full Text] [Related]
14. Pathology-based risk stratification of muscle-invasive bladder cancer patients undergoing cystectomy for persistent disease after induction chemoradiotherapy in bladder-sparing approaches. Koga F; Fujii Y; Masuda H; Numao N; Yokoyama M; Ishioka J; Saito K; Kawakami S; Kihara K BJU Int; 2012 Sep; 110(6 Pt B):E203-8. PubMed ID: 22289431 [TBL] [Abstract][Full Text] [Related]
15. Radiation-Induced Reprogramming of Pre-Senescent Mammary Epithelial Cells Enriches Putative CD44(+)/CD24(-/low) Stem Cell Phenotype. Gao X; Sishc BJ; Nelson CB; Hahnfeldt P; Bailey SM; Hlatky L Front Oncol; 2016; 6():138. PubMed ID: 27379202 [TBL] [Abstract][Full Text] [Related]
16. CD44 and SSEA-4 positive cells in an oral cancer cell line HSC-4 possess cancer stem-like cell characteristics. Noto Z; Yoshida T; Okabe M; Koike C; Fathy M; Tsuno H; Tomihara K; Arai N; Noguchi M; Nikaido T Oral Oncol; 2013 Aug; 49(8):787-95. PubMed ID: 23768762 [TBL] [Abstract][Full Text] [Related]
17. MicroRNA-34a functions as an anti-metastatic microRNA and suppresses angiogenesis in bladder cancer by directly targeting CD44. Yu G; Yao W; Xiao W; Li H; Xu H; Lang B J Exp Clin Cancer Res; 2014 Dec; 33(1):779. PubMed ID: 25551284 [TBL] [Abstract][Full Text] [Related]
18. Clinical significance of CD44 variant 9 expression as a prognostic indicator in bladder cancer. Kobayashi K; Matsumoto H; Matsuyama H; Fujii N; Inoue R; Yamamoto Y; Nagao K Oncol Rep; 2016 Nov; 36(5):2852-2860. PubMed ID: 27599396 [TBL] [Abstract][Full Text] [Related]
19. CD44 and RHAMM are essential for rapid growth of bladder cancer driven by loss of Glycogen Debranching Enzyme (AGL). Oldenburg D; Ru Y; Weinhaus B; Cash S; Theodorescu D; Guin S BMC Cancer; 2016 Sep; 16(1):713. PubMed ID: 27595989 [TBL] [Abstract][Full Text] [Related]
20. Effect of Tumor Burden on Tumor Aggressiveness and Immune Modulation in Prostate Cancer: Association with IL-6 Signaling. Wu CT; Huang YC; Chen WC; Chen MF Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31315262 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]